Positron emission tomography in uro-oncology
Author:
- 1 January 2005
- journal article
- Published by E-MED LTD in Cancer Imaging
- Vol. 5 (1) , 1-7
Abstract
Positron emission tomography (PET) in uro-oncology has been one of the slowest areas to develop. There are problems because of the excretion of tracer through the renal tract. Its use in prostate cancer has generally being disappointing, with PET being unable to differentiate malignancy from benign prostatic hypertrophy. In more advanced disease and in the search for the site of recurrence, PET can be of more use. Also, new tracers may prove to be more effective. PET has been shown to be of value in testicular cancer, particularly in defining recurrent disease in residual masses and in patients with raised markers. There is a clear place for PET in some of these cases. Early studies at staging are promising but more work is required to define its exact place. In renal and bladder cancer, PET may be a useful adjunct to conventional imaging in difficult cases and may assist in local staging. In all tumours it is valuable to differentiate fibrosis from recurrent disease in the treatment bed, an area of difficulty for CT/MR.Keywords
This publication has 47 references indexed in Scilit:
- 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.2003
- Diagnostic Value of 18F-FDG Positron Emission Tomography for Detection and Treatment Control of Malignant Germ Cell TumorsUrologia Internationalis, 2002
- Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [18F]FDG PETBritish Journal of Cancer, 2002
- FDG–PET. A possible prognostic factor in head and neck cancerBritish Journal of Cancer, 2002
- Predictive Impact of 2-18Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky SeminomaJournal of Clinical Oncology, 2001
- Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary ChemotherapyJournal of Clinical Oncology, 2000
- Positron emission tomography detection of osseous metastases of renal cell carcinoma not identified on bone scanUrology, 2000
- Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography Is Useless for the Detection of Local Recurrence after Radical ProstatectomyEuropean Urology, 1999
- Detection of bony metastases of androgen-independent prostate cancer by PET-FDGNuclear Medicine and Biology, 1996
- Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients.Journal of Clinical Oncology, 1996